Oracle Corp. (NYSE:ORCL) stock fell nearly 2% in Thursday’s premarket trading as risk appetite weakened. Nasdaq futures are down 0.90%, while S&P 500 futures have shed 0.50%.
Separately, Oracle announced several new products and partnerships Wednesday across digital assets and health care.
Digital Money Push
Oracle expanded its Digital Assets Data Nexus platform to help regulated banks integrate digital money with existing payment and banking systems.
The update adds payment-execution integrations, configurable wallet and smart-contract controls, and AI-enabled monitoring designed to support governance, compliance and risk management.
The platform will support ISO 20022-based payment operations, prebuilt integration with Oracle Banking Payments and connectivity with Swift Ledger.
Oracle said the system can also use AI to flag transaction anomalies, liquidity pressures and other emerging risks while enabling policy-controlled responses.
AI-Powered Cancer Care
Oracle also launched Oracle Health Oncology EHR, a new electronic health record system designed specifically for cancer care.
The platform combines oncology workflows, AI-driven clinical intelligence and connected patient information to support care from diagnosis through treatment and follow-up.
Oracle said the system will include AI assistants, unified cancer-care timelines and tools that combine genomic, imaging, pathology, laboratory and pharmacy data.
The company also plans capabilities for chemotherapy and immunotherapy regimen planning, care coordination and treatment decision support.
Oracle Health Adds AI To Revenue Cycle
The company also announced new AI capabilities across its Oracle Health revenue cycle management portfolio, with general availability planned in the coming months.
The tools are designed to identify reimbursement risks earlier across scheduling, financial clearance, clinical documentation, charge capture, billing and payments.
Oracle said the capabilities will support prior authorization, documentation quality, charge capture, medical coding and appeals management.
The company also plans to connect reimbursement workflows with Oracle Fusion Cloud Applications to link financial reconciliation, revenue accounting, treasury management and analytics.
Analyst Outlook
Oracle trades at a price-to-earnings ratio of about 22.7. The stock carries a Buy consensus rating with an average price forecast of $249.64.
Freedom Broker maintained a Buy rating on Sept. 14 but lowered its price forecast to $205. Argus Research maintained its Buy rating and $225 price forecast the same day. Stifel maintained a Buy rating on Sept. 11 and lowered its price forecast to $200.
ETFs With Significant Oracle Exposure
ORCL is a major holding in several technology-focused exchange-traded funds.
The iShares Expanded Tech-Software Sector ETF (BATS:IGV) has a 5.82% weighting in ORCL. The First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:TDIV) and FT Vest Technology Dividend Target Income ETF (NASDAQ:TDVI) each have a 5.64% weighting.
Large inflows or outflows from these ETFs can contribute to buying or selling activity in ORCL shares.
Technical Analysis
ORCL is trading about 4.8% below its 20-day simple moving average of $149.84. However, the stock remains about 0.5% above its 50-day SMA of $141.85.
The longer-term picture remains weaker. ORCL is about 11.9% below its 100-day SMA of $161.80 and 13.7% below its 200-day SMA of $165.35.
The relative strength index stands at 47.28. That is a neutral reading and suggests the stock is neither overbought nor oversold.
ORCL’s 20-day SMA remains above its 50-day SMA, providing some short-term support. However, the 50-day SMA remains below the 200-day SMA following a January death cross.
Resistance stands near $159.50. Support is around $139.
ORCL Stock Slides Premarket
Oracle shares were down 1.58% at $142.28 in Thursday’s premarket trading, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment